The controversy around a potential increase in incidence of depression in MS patients treated with interferon betas was not resolved until subsequent trials used validated rating scales for depression, which found no significant increase, and meta-analyses confirming these conclusions were published years after drug approval [33,34]. This evidence concerns the gene IFNB1 and myeloid sarcoma.